Loading...
Loading...
ISEE| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 34.7M |
| Operating I/L | -34.7M |
| Other Income/Expense | 0.1M |
| Interest Income | 0.1M |
| Pretax | -34.5M |
| Income Tax Expense | -0.3M |
| Net Income/Loss | -34.3M |
IVERIC bio, Inc. is a biopharmaceutical company specializing in the discovery and development of innovative treatments for retinal diseases, particularly age-related and orphan inherited retinal diseases (IRDs). The company's primary focus is on advancing its lead product, Zimura, an inhibitor of complement factor C5, through clinical trials for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). Additionally, IVERIC bio is developing other potential therapies for various retinal diseases, including leber congenital amaurosis type 10 (LCA10), autosomal recessive stargardt disease (STGD1), and rhodopsin-mediated autosomal dominant retinitis pigmentosa.
